Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Editas Medicine, Inc.NASDAQ: EDIT

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$23.43M, compared with -$71.96M a year earlier. Trailing-twelve-month EBITDA was -$100.08M.

Context

  • EBITDA amounted to 366.8% of revenue in FY2025, down 354.6 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of -$58.03M (+61.0%) for the fiscal year ending Dec 2026, a step up from the +36.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.43M-343.8% QoQ
Last fiscal yearDec 2025
-$148.61M+36.2% YoY
LTMMar 2026
-$100.08M+56.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+67.4%+18.8%-48.6 pp
1 year+36.2%+61.0%+24.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(148.61M) USD
Year-over-year change
+36.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's LTM Mar 2026 EBITDA of -$100.08M is the 4th highest of the 9 companies compared; the peer median is -$151.43M.
  • Its year-over-year change of +56.8% is the 2nd highest of 9, against a peer median of +11.7%.
  • EBITDA amounts to 258.7% of revenue for EDIT, versus a peer median of 790.7%.
EDIT Competitors Peer median
EBITDA for EDIT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M -143.9%—89.7%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.46M -44.4%——
BEAMBeam Therapeutics Inc.LTM Jun 2026-$63.18M +83.2%—40.5%
EDITEditas Medicine, Inc.LTM Mar 2026-$100.08M +56.8%—258.7%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$111.97M +23.4%—999.5%
PRMEPrime Medicine, Inc.LTM Mar 2026-$190.9M +2.4%—4732.2%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$194.47M +21.0%——
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$384.61M +25.4%—581.9%
CRSPCRISPR Therapeutics AGLTM Sep 2026-$482.67M -3.6%—1917.5%
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding EDIT) -$151.43M+11.7%—790.7%

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.54M19.71M78.12M32.31M40.52M
Cost of Revenue5.05M6.34M6.06M199.25M0
Gross Profit20.49M13.38M72.06M(166.93M)40.52M
Gross Margin80.2%67.9%92.2%-516.6%100.0%
Research & Development142.51M174.96M177.65M199.25M89.95M
Selling, General & Admin76.18M70.7M69.65M71.99M49.9M
Operating Expenses213.64M239.33M241.24M84.22M139.86M
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
EBITDA(187.45M)(214.1M)(147.16M)(233.11M)(148.61M)
EBITDA Margin-733.8%-1086.1%-188.4%-721.4%-366.8%
Operating Income(193.15M)(225.95M)(169.18M)(251.15M)(99.34M)
Operating Margin-756.1%-1146.3%-216.6%-777.2%-245.2%
Interest Income607K5.52M17.57M14.06M8.31M
Interest Expense00006.17M
Other Income / Expenses644K5.52M15.96M14.06M(60.72M)
Income Before Tax(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Pre-Tax Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
Income Tax Expense00000
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Net Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
EPS (Basic)(2.85)(3.21)(2.02)(2.88)(1.80)
EPS (Diluted)(2.85)(3.21)(2.02)(2.88)(1.80)
Weighted Avg Shares67.62M68.66M75.97M82.34M88.75M
Weighted Avg Shares (Diluted)67.62M68.66M75.97M82.34M88.75M

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.